Departments of Neurology, John Hunter Hospital, University of Newcastle, Newcastle, Australia.
Department of Neurology, the Second Affiliated Hospital of Zhejiang University, Hangzhou, China.
Ann Neurol. 2016 Aug;80(2):286-93. doi: 10.1002/ana.24714. Epub 2016 Jul 26.
Although commonly used in clinical practice, there remains much uncertainty about whether perfusion computed tomography (CTP) should be used to select stroke patients for acute reperfusion therapy. In this study, we tested the hypothesis that a small acute perfusion lesion predicts good clinical outcome regardless of thrombolysis administration.
We used a prospectively collected cohort of acute ischemic stroke patients being assessed for treatment with IV-alteplase, who had CTP before a treatment decision. Volumetric CTP was retrospectively analyded to identify patients with a small perfusion lesion (<15ml in volume). The primary analysis was excellent 3-month outcome in patients with a small perfusion lesion who were treated with alteplase compared to those who were not treated.
Of 1526 patients, 366 had a perfusion lesion <15ml and were clinically eligible for alteplase (212 being treated and 154 not treated). Median acute National Institutes of Health Stroke Scale score was 8 in each group. Of the 366 patients with a small perfusion lesion, 227 (62%) were modified Rankin Scale (mRS) 0 to 1 at day 90. Alteplase-treated patients were less likely to achieve 90-day mRS 0 to 1 (57%) than untreated patients (69%; relative risk [RR] = 0.83; 95% confidence interval [CI], 0.71-0.97; p = 0.022) and did not have different rates of mRS 0 to 2 (72% treated patients vs 77% untreated; RR, 0.93; 95% CI, 0.82-1.95; p = 0.23).
This large observational cohort suggests that a portion of ischemic stroke patients clinically eligible for alteplase therapy with a small perfusion lesion have a good natural history and may not benefit from treatment. Ann Neurol 2016;80:286-293.
尽管在临床实践中广泛应用,但对于是否应使用灌注 CT(CTP)来选择急性再灌注治疗的卒中患者,仍存在很多不确定性。在本研究中,我们检验了这样一个假设,即小的急性灌注病灶无论是否给予溶栓治疗,均可预测良好的临床结局。
我们使用了一组前瞻性收集的急性缺血性卒中患者队列,这些患者在决定治疗前进行了 CTP 检查。回顾性分析容积 CTP 以确定存在小灌注病灶(体积<15ml)的患者。主要分析是小灌注病灶患者接受阿替普酶治疗与未接受治疗相比,3 个月时的良好临床结局。
在 1526 例患者中,366 例存在<15ml 的灌注病灶且适合接受阿替普酶治疗(212 例接受治疗,154 例未接受治疗)。两组的急性 NIHSS 评分中位数均为 8。在 366 例小灌注病灶患者中,227 例(62%)在第 90 天时 mRS 评分为 0-1。接受阿替普酶治疗的患者 90 天 mRS 评分为 0-1 的可能性低于未接受治疗的患者(57% vs 69%;相对风险[RR]为 0.83;95%置信区间[CI]为 0.71-0.97;p=0.022),两组 mRS 评分为 0-2 的比例也没有差异(接受治疗的患者为 72%,未接受治疗的患者为 77%;RR 为 0.93;95%CI 为 0.82-1.95;p=0.23)。
本大型观察性队列研究表明,一部分临床适合接受阿替普酶治疗的小灌注病灶缺血性卒中患者具有良好的自然病史,可能不会从治疗中获益。